Several studies suggest that only 3% of CRC patients have HER2 overexpression, with a higher prevalence in RAS/BRAF wild-type tumors at about 5–14% of cases [40,41,42,43], as they enhance HER2 amplification [36]. Here, BRAF is linked to colorectal carcinoma.